CN106715680A - 用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 - Google Patents
用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 Download PDFInfo
- Publication number
- CN106715680A CN106715680A CN201580035822.6A CN201580035822A CN106715680A CN 106715680 A CN106715680 A CN 106715680A CN 201580035822 A CN201580035822 A CN 201580035822A CN 106715680 A CN106715680 A CN 106715680A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium longum
- cbt
- bifidobacterium
- kctc
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001608472 Bifidobacterium longum Species 0.000 title claims abstract description 97
- 229940009291 bifidobacterium longum Drugs 0.000 title claims abstract description 97
- 230000012010 growth Effects 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 230000001737 promoting effect Effects 0.000 title claims abstract description 14
- 235000013376 functional food Nutrition 0.000 title abstract 2
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 25
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 25
- 235000020256 human milk Nutrition 0.000 claims abstract description 24
- 210000004251 human milk Anatomy 0.000 claims abstract description 24
- 230000001580 bacterial effect Effects 0.000 claims description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 241000186000 Bifidobacterium Species 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 17
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 5
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 5
- 102000019199 alpha-Mannosidase Human genes 0.000 claims description 4
- 108010012864 alpha-Mannosidase Proteins 0.000 claims description 4
- 235000013406 prebiotics Nutrition 0.000 claims description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 238000011161 development Methods 0.000 abstract description 8
- 230000029087 digestion Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 description 15
- 230000003115 biocidal effect Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 238000004321 preservation Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 229920000297 Rayon Polymers 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 238000001976 enzyme digestion Methods 0.000 description 6
- -1 jade Rice starch Chemical compound 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000004641 brain development Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229930000044 secondary metabolite Natural products 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241001468191 Lactobacillus kefiri Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101150057615 Syn gene Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940052337 quinupristin/dalfopristin Drugs 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 230000019702 secondary metabolite biosynthetic process Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 101100462438 Mus musculus Otulin gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000970807 Thermoanaerobacterales Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- DLRVVLDZNNYCBX-LIZSDCNHSA-N beta-D-Glcp-(1->6)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- ZBDGHWFPLXXWRD-JGWLITMVSA-N methyl beta-D-xylopyranoside Chemical compound CO[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZBDGHWFPLXXWRD-JGWLITMVSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical class [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种长双歧杆菌CBT BG7双歧杆菌,其具有优异的生长促进效果并且国际保藏于韩国生物科学和生物技术研究所的韩国典型培养物保藏中心(KCTC),保藏号为KCTC 12200BP。本发明的菌株通过促进人乳寡糖的消化以增强免疫力和体力从而具有促进生长的有益效果。
Description
技术领域
本发明概括而言涉及一种用于促进生长的长双歧杆菌(Bifidobacteriumlongum)CBT BG7菌株以及用于促进生长的含有该菌株的营养组合物,并且更具体地涉及一种能够通过促进人乳的消化并合成维生素而促进新生儿、婴儿、幼儿和成长儿童的生长的长双歧杆菌CBT BG7菌株,并且涉及一种用于促进生长的营养组合物,该营养组合物含有所述长双歧杆菌CBT BG7菌株。
背景技术
人类生长发生在直到***的时期,其中大多数生长板仍然是开放的。生长在医学上可以被定义为伴随成熟的大小的变化,并且具体地,术语“儿童生长”意在不仅包括身高的增加,而且还包括身体的每个器官的大小和功能的增加。
人们普遍认为人类的生长受遗传因素的影响最大。然而,事实上,遗传因素对人类生长的影响只有23%左右,其余77%由出生后因素决定。近年来,由于经济持续增长、西化饮食习惯、改善营养状况等,大大增加了儿童和青少年的生长和发育。另外,在社会氛围重视(其中外部外观和身高被认为是重要的)的情况下,生长越来越受到人们的关注。
迄今为止,已知的促进生长的方法包括施用生长激素剂的方法。然而,使用生长激素非常昂贵并且可能引起不良作用,包括各种症状如注射部位的瘙痒、病发作、脂肪萎缩、高血压、葡萄糖不耐受、胰腺炎、全身过敏反应、生长激素抗体阳性反应、癌症发展和男性中的男性***发育。因此,迫切需要开发能够基本上有助于生长的安全且有效的食品材料。
韩国专利No.0887377(名称为“婴儿和青少年的健康补充食品(Healthsupplement food for babies and teenagers)”)、韩国专利No.10530211(名称为“用于改善学习能力的功能保健食品组合物及其制备方法(Functional health food compositionfor improving learning ability and preparation method thereof)”)、韩国专利No.0561286(名称为“用于促进生长发育的含有干酵母,天然提取物粉末和营养成分混合粉末的健康功能组合物(Health functional composition for promotion of growth anddevelopment containing dried yeast,natural extract powder and mixed powder ofnutritive components)”)等提议了用于促进生长的食物。然而,这些食物具有的生长促进效果不能达到预期。
发明内容
技术问题
本发明人进行了广泛的努力以发现具有优异的生长促进效果的益生菌,并因此在实验上发现了长双歧杆菌CBT BG7菌株作为生长促进产品的适用性,由此完成了本发明。本发明的一个目的是提供一种长双歧杆菌CBT BG7菌株,其适用于促进新生儿、婴儿、幼儿和成长儿童的生长。
本发明的另一个目的是提供一种营养组合物,其通过促进人乳寡糖的消化、促进维生素合成和抑制有害细菌的增殖而能够促进新生儿、婴儿、幼儿和成长儿童的生长。
技术方案
为了实现上述目的,本发明的一个方面涉及提供用于促进生长的长双歧杆菌CBTBG7双歧杆菌,其国际保藏于韩国生物科学和生物技术研究所的韩国典型培养物保藏中心(KCTC),保藏号为KCTC 12200BP。
本发明的另一方面涉及提供能够促进婴儿、幼儿和成长儿童生长的营养组合物,其含有本发明的长双歧杆菌CBT BG7菌株。
有益效果
本发明的长双歧杆菌CBT BG7菌株通过消化和供应人乳寡糖而展示出优异的生长促进作用,所述人乳寡糖难以在工业上大量产生并且不被人类酶消化,其也促进维生素生物合成、抑制有害肠细菌的增殖、促进有益细菌的生长和调节免疫***。
根据本发明所述的促进生长的营养组合物通过激活代谢平衡和调节免疫***而可以促进新生儿、婴儿、幼儿和成长儿童的生长和发育,并且其还可以促进大脑发育。另外,根据本发明所述的促进生长的营养组合物可以减轻生长迟缓、发育迟缓、体力降低和低体重。
附图说明
图1显示了根据本发明所述的长双歧杆菌CBT BG7菌株(KCTC 12200BP)的16SrRNA序列,并且还显示了本发明的长双歧杆菌CBT BG7菌株与相关物种之间的16S rRNA序列同源性和***发育关系的比较;
图2显示了根据本发明所述的长双歧杆菌CBT BG7菌株的基因组DNA的RAPD(随机扩增多态性DNA)分析的结果;
图3显示了根据本发明所述的长双歧杆菌CBT BG7菌株(KCTC 12200BP)的基因组DNA的PFGE(脉冲场凝胶电泳)分析的结果;
图4显示了本发明的长双歧杆菌CBT BG7菌株和相关的双歧杆菌属物种的***发育树;
图5显示了根据本发明所述的长双歧杆菌CBT BG7菌株的人乳低聚糖代谢相关基因的数目;
图6显示了次级代谢产物生物合成基因是否存在于本发明的长双歧杆菌CBT BG7菌株中;和
图7是显示本发明的长双歧杆菌CBT BG7菌株对小鼠生长的生长促进效果的图谱。
具体实施方式
在下文中,将更详细地描述本发明。
本发明的一个方面涉及长双歧杆菌CBT BG7菌株,其具有优异的生长促进效果,并且国际保藏于韩国生物科学和生物技术研究所的韩国典型培养物保藏中心(KCTC),保藏号为KCTC 12200BP。
根据本发明所述的长双歧杆菌CBT BG7菌株可以通过消化人乳寡糖(HMOs)——所述人乳寡糖由于结构非常复杂而不被人类酶消化并且难以大量工业化生产——并且通过向接受该菌株的婴儿或幼儿供应人乳寡糖,并且还通过产生可以在人体中用作营养物的代谢物例如维生素来促进新生儿、婴儿和成长儿童的生长和发育。
已知人乳含有200种以上具有有用功能的寡糖。已知人乳低聚糖促进有益肠微生物菌群的增殖和繁殖、抑制有害细菌的增殖、作为细胞反应的调节剂、调节免疫***,并且通过提供作为新生儿和婴儿脑部生长发育所必需成分的脑活动能量而有助于新生儿和婴儿的大脑发育。
人乳寡糖在上胃肠道和小肠中具有抵抗酶消化的能力,并因此到达结肠而不被损坏并且在结肠中用作发酵的底物。据认为,人乳含有几种因子,其促进抑制病原微生物增殖的有益肠微生物菌群的增殖。一种使得人乳寡糖能够增加有益细菌的数量并减少潜在病原菌的数量的方法,其通过竞争细胞表面受体、竞争必需营养素、产生抗菌剂、以及产生抑制化合物如单链脂肪酸(SCFAs)而发生,所述单链脂肪酸可以降低***物的pH并抑制潜在的病原菌。人乳寡糖被发酵以产生SCFAs,例如乙酸、丙酸和丁酸。据认为,这种SCFAs有助于卡路里、作为肠上皮的主要能量来源、刺激结肠中的钠和水的吸收、并且增强小肠中的消化和吸收。另外,SCFAs通过调节胃肠道发育和免疫功能来促进一般胃肠道健康。
人乳寡糖(HMOs)由各种寡糖组成,主要有五种单糖:D-葡萄糖(Glc)、D-半乳糖(Gal)、N-乙酰氨基葡萄糖(GlcNAc)、L-岩藻糖(Fuc)和唾液酸(Sia;N-乙酰神经氨酸[Neu5Ac])。
根据本发明所述的短长双歧杆菌CBT BG7菌株的基因组包括编码消化人乳寡糖(HMOs)的酶的各种基因,所述酶诸如水解α-甘露糖的α-甘露糖苷酶、水解β-半乳糖的β-半乳糖苷酶、和内桥-α-N-乙酰葡糖胺糖苷酶,该内桥-α-N-乙酰葡糖胺糖苷酶水解α-甘露糖苷酶以及粘蛋白与粘蛋白型糖蛋白的丝氨酸和苏氨酸残基的半乳糖基-β-1,3-N-乙酰基-半乳糖胺的α键。
另外,根据本发明所述的长双歧杆菌CBT BG7菌株的基因组可以从L-天冬氨酸合成B族维生素中的烟酸(B3)。
根据本发明的另一方面,本发明的长双歧杆菌CBT BG7菌株可用作益生菌双歧杆菌或可用于各种乳制品和其他发酵产物中。
本发明的另一方面涉及用于促进生长的营养组合物,其含有本发明的长双歧杆菌CBT BG7菌株。目前,人乳寡糖(HMOs)不能大量生产也不可商购,因此不被包含在大多数配方奶或配方食品中。虽然人乳寡糖(HMOs)是婴儿的必需营养源,但是这些寡糖不被人类酶消化,并且如果这些寡糖不被消化,则被作为粪便***出。根据本发明所述的用于促进生长的营养组合物可以通过消化和供应人乳寡糖来促进新生儿和婴儿的大脑发育和生长。食品组合物是食品、补充剂、益生菌或共生体。本文使用的术语“益生菌”是指当以合适量提供时有益于宿主生物体健康的活微生物。本文使用的术语“共生体”是指含有益生元(prebiotic)和益生菌的混合物的食品。
在一些实施方式中,除了长双歧杆菌CBT BG7菌株之外,本发明的组合物还可以含有一种或多种乳酸菌或双歧杆菌菌株,它们选自于由唾液乳杆菌(Lactobacillussalivarius)、短乳杆菌(Lactobacillus brevis)、瑞士乳杆菌(Lactobacillushelveticus)、发酵乳杆菌(Lactobacillus fermentum)、副干酪乳杆菌(Lactobacillusparacasei)、干酪乳杆菌(Lactobacillus casei)、德氏乳杆菌(Lactobacillusdelbrueckii)、罗伊氏乳杆菌(Lactobacillus reuteri)、布氏乳杆菌(Lactobacillusbuchneri)、加氏乳杆菌(Lactobacillus gasseri)、约氏乳杆菌(Lactobacillusjohonsonii)、高加索酸奶乳杆菌(Lactobacillus kefir)、乳酸乳球菌(Lactococcuslactis)、两歧双歧杆菌(Bifidobacterium bifidum)、假长双歧杆菌(Bifidobacteriumpseudolongum)、嗜热双歧杆菌(Bifidobacterium themophilum)和青春双歧杆菌(Bifidobacterium adolescentis)组成的组。
根据本发明所述的长双歧杆菌CBTBG7菌株可以通过在通常用于双歧杆菌培养的培养基中培养而增殖,并且可以从培养物中回收。培养后得到的培养物可以原封不动地使用,如果需要,可以进行使用离心的粗纯化和/或进行使用过滤或灭菌操作的固液分离。优选地,仅通过离心回收双歧杆菌细胞。此外,用于本发明的双歧杆菌可以是湿细胞或干细胞。例如,可以通过冻干将双歧杆菌配制为益生菌并在该状态下使用。
除了长双歧杆菌CBT BG7菌株外,本发明的组合物还可以含有常规载体或赋形剂。另外,本发明的组合物可以与各种添加剂诸如粘合剂、崩解剂、包衣剂、润滑剂等一起配制。
本发明的组合物可以通过将长双歧杆菌CBT BG7菌株与合适的载体、赋形剂、其它活性成分等混合而配制为粉末、颗粒、片剂或液体的形式。此外,本发明的菌株可以使用已知的方法进行肠溶包衣,使得活性成分双歧杆菌在通过胃肠道后到达结肠,并且将在肠中快速释放。
可用于本发明的赋形剂包括糖类如蔗糖、乳糖、甘露糖醇或葡萄糖,以及淀粉如玉米淀粉、马铃薯淀粉或部分预胶化淀粉。可用于本发明的粘合剂包括多糖,诸如糊精、海藻酸钠、角叉菜胶、瓜尔胶、***树胶、琼脂等;天然存在的大分子物质,诸如黄蓍胶、明胶、谷蛋白等;纤维素衍生物,诸如羟丙基纤维素、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、羟丙基乙基纤维素、羧甲基纤维素等;和聚合物,诸如聚乙烯吡咯烷酮、聚乙烯醇、聚乙酸乙烯酯、聚乙二醇、聚丙烯酸、聚甲基丙烯酸和乙酸乙烯酯树脂。
可用于本发明的崩解剂包括纤维素衍生物,诸如羧甲基纤维素、羧甲基纤维素钙、低取代羟丙基纤维素等;和淀粉,诸如羧甲基淀粉钠、羟丙基淀粉、玉米淀粉、马铃薯淀粉、米淀粉和部分预胶化淀粉。
可用于本发明的润滑剂的实例包括滑石粉、硬脂酸、硬脂酸钙、硬脂酸镁、胶体二氧化硅、含水二氧化硅、各种蜡和油等。
可用于本发明的包衣剂包括水不溶性聚合物,诸如甲基丙烯酸二甲氨基乙酯-甲基丙烯酸共聚物、聚乙烯缩乙醛二乙基氨基乙酸酯、丙烯酸乙酯-甲基丙烯酸共聚物、丙烯酸乙酯-甲基丙烯酸甲酯-甲基丙烯酸氯代三甲基铵乙基酯共聚物、乙基纤维素等;肠溶聚合物,诸如甲基丙烯酸-丙烯酸乙酯共聚物、羟丙基甲基纤维素邻苯二甲酸酯、羟丙基甲基纤维素乙酸琥珀酸酯等;和水溶性聚合物,诸如甲基纤维素、羟丙基甲基纤维素、聚乙烯吡咯烷酮、聚乙二醇等,但不必限于此。
根据本发明所述的促进生长用的组合物中,活性成分长双歧杆菌CBT BG7菌株的含量可以根据受试者的体重、年龄或性别来适当确定。例如,本发明的组合物相对于该组合物的总重量以营养有效浓度含有作为活性成分的长双歧杆菌CBT BG7菌株。优选地,所述组合物含有量为108~1012cfu/g的长双歧杆菌CBT BG7菌株或含有具有相同数量活细菌的培养物产品。通常,对于成人,可以根据需要服用一次或多次1×106个以上活细菌,优选1×108至1×1012个活细菌。
在另一方面,根据本发明所述的用于促进生长的营养组合物可以进一步包含从由长双歧杆菌bv.婴儿CBT BT1(KCTC 11859BP)、短双歧杆菌CBT BR3(KCTC 12201BP)和两歧双歧杆菌CBT BF3(KCTC 12199BP)组成的组中选择的一种或多种其它益生元。该组合物可以以相同的百分比含有每种双歧杆菌菌株。
在下文中,将参考实施例描述本发明。然而,应当理解的是,这些实施例仅用于说明性目的,而不意图限制本发明的范围。
实施例
实施例1:长双歧杆菌CBT BG7菌株的分离和鉴定
1-1:新型菌株的选择
将1g人粪便连续稀释在无菌无氧水中,并将1ml每种稀释液倒在葡萄糖血肝(BL.BD.USA)固体培养基上,并在厌氧条件下培养3天。使用通过将BCP(溴甲酚紫,0.17g/L)添加至BL中获得的双歧杆菌选择培养基对产生的菌落进行选择,然后在相同条件下培养3天。选择周围的颜色变为黄色的双歧杆菌菌落,然后对所选择的菌落进行生物化学和分子生物学鉴定。此后,选择具有最佳物理性质的一种菌株。
1-2:选定菌株的鉴定
1)糖利用的分析
使用API 50CHL试剂盒检查从人粪便中分离出的菌株的糖利用。使用API网(https://apiweb.biomerieux.com)分析通过检查糖利用所获得的结果,并且将分析的结果示于下表1中:
表1
序号 | 碳水化合物 | 利用 | 序号 | 碳水化合物 | 利用 |
0 | 对照 | - | 25 | 七叶灵 | + |
1 | 甘油 | - | 26 | 水杨苷 | + |
2 | 赤藻糖醇 | - | 27 | 纤维二糖 | - |
3 | D-***糖 | - | 28 | 麦芽糖 | + |
4 | L-***糖 | + | 29 | 乳糖 | + |
5 | 核糖 | + | 30 | 蜜二糖 | + |
6 | D-木糖 | + | 31 | 蔗糖 | + |
7 | L-木糖 | - | 32 | 海藻糖 | - |
8 | 阿东糖 | - | 33 | 菊粉 | - |
9 | β-甲基木糖苷 | - | 34 | 松三糖 | - |
10 | 半乳糖 | + | 35 | D-棉子糖 | + |
11 | D-葡萄糖 | + | 36 | *** | - |
12 | D-果糖 | + | 37 | 糖基 | - |
13 | D-甘露糖 | + | 38 | 木糖醇 | - |
14 | L-山梨糖 | - | 39 | β-龙胆二糖 | - |
15 | 鼠李糖 | - | 40 | D-土瑞糖 | w |
16 | 半乳糖醇 | - | 41 | D-来苏糖 | - |
17 | 肌醇 | - | 42 | D-塔格糖 | - |
18 | 甘露糖醇 | + | 43 | D-岩藻糖 | - |
19 | 山梨糖 | + | 44 | L-岩藻糖 | - |
20 | α-甲基-D-甘露糖苷 | - | 45 | D-***糖醇 | - |
21 | α-甲基-D-葡糖苷 | + | 46 | L-***糖醇 | - |
22 | N-乙酰葡萄糖胺 | - | 47 | 葡萄糖酸盐 | - |
23 | 杏仁苷 | - | 48 | 2-酮-葡萄糖酸 | - |
24 | 熊果苷 | + | 49 | 5-酮-葡萄糖酸 | w |
2)16s rRNA鉴定
为了使用分子生物学方法鉴别所选择的菌株,分析了该菌株的16s rRNA序列。通过使用Accuprep基因组提取试剂盒(Bioneer,Korea)从1ml菌株(从粪便中分离)的纯培养物中提取基因组DNA。以提取的DNA为模板,使用引物F(5’-AGAGTTTGATCCTGGCTCAG-3’)和引物R(5’-AAGGAGGTGATCCAGCC-3’),通过PCR(MyCycler,BIO-RAD,USA)扩增16s rRNA区域。将PCR产物连接到pGEM-Teasy载体(Promega,USA)上并且转化到大肠杆菌DH5α菌株中,之后将其接种在LB/x-gal/amp平板上,并在37℃下培养过夜。通过筛选从转化体中分离含有***片段的重组质粒,随后进行DNA测序。在DNA测序中,使用DNA星程序的簇V方法,分析分离的菌株与各种双歧杆菌sp.菌株(包括长双歧杆菌T(ATCC 15707))的同源性。如图1所示,分离菌株的16s rRNA序列显示出与长双歧杆菌T(ATCC 15707)99.1%的同源性。
3)RAPD(随机扩增多态性DNA)分析
为了RAPD分析,从分离自粪便的长双歧杆菌CBT BG7菌株中提取基因组DNA。使用分离的DNA作为模板,使用(GTG)5(5’-GTGGTGGTGGTGGTG-3’)引物进行PCR-RAPD(MyCycler,BIO-RAD,USA)。使用EtBr将所得PCR产物染色,然后使用G:BOX(SYNGENE,UK)观察。此外,在PFGE分析中,将纯培养的长双歧杆菌CBT BG7菌株调整至OD600=4的最终OD,以构建胶块(plug)。然后,使用各种酶消化基因组DNA并进行电泳,之后比较对照长双歧杆菌T(ATCC15707)进行分析。
如从图2中可以看出,RAPD的结果表明,长双歧杆菌CBT BG7菌株显示出与长双歧杆菌T(ATCC 15707)不同的条带模式。在图2中,泳道1表示长双歧杆菌T(ATCC 15707)的结果,且泳道2表示长双歧杆菌CBT BG7菌株的结果。基于上述结果,发现从粪便中分离出的微生物长双歧杆菌CBT BG7是与长双歧杆菌T(ATCC 15707)不同的新型菌株。
4)PFGE(脉冲场凝胶电泳)分析
测量了纯培养在BL肉汤中的长双歧杆菌CBT BG7的O.D.,然后使用2%低熔点琼脂糖将其调节至最终的O.D.,O.D600=4,从而构成胶块。然后,使用各种酶消化基因组DNA并进行电泳,之后比较对照长双歧杆菌T(ATCC 15707)进行分析。
将构建的胶块置于1ml溶菌酶缓冲液(2mg/ml溶菌酶(Sigma),0.05%N-十二烷基肌氨酸(Sigma))中,并向其中加入10μl4mg/ml溶葡萄球菌素(Sigma),随后在37℃温育过夜。小心地取出胶块并且加入到4ml NDS缓冲液(1ml 1M Tris-HCl(pH=8.0),10ml100%SDS,89ml 0.5M EDTA(pH=8.5))中,随后在50℃温育过夜。接下来,轻微振荡,用10ml 50mMEDTA(pH8.5)将胶块洗涤6次,然后小心地转移到400μl待处理的酶缓冲液中,随后在室温下温育30分钟。将各个胶块转移到400μl新鲜的酶缓冲液中并且向其中加入限制酶(20U),随后在37℃温育过夜。作为限制酶,使用XbaI和ApaI。使用CHEF***(BIO-RAD,USA)在0.5XTBE中以5.3cm/V和脉冲时间1s至15s进行电泳18小时。
电泳完成后,将胶块用EtBr溶液染色,并用G:BOX(SYNGENE,UK)观察其带状图案。使用XbaI和ApaI进行的PFGE的结果表明,从粪便中分离的长双歧杆菌CBT BG7是新型菌株,其显示出与长双歧杆菌T(ATCC 15707)不同的带状图案。在图3中,泳道1表示长双歧杆菌T(ATCC 15707)的结果,且泳道2表示长双歧杆菌CBT BG7的结果。
5)酶活性试验
为了测量长双歧杆菌CBT BG7的酶活性,使用API ZYM试剂盒检查酶的差异。当将长双歧杆菌CBT BG7的酶活性与长双歧杆菌T(ATCC 15707)进行比较时,长双歧杆菌CBTBG7显示出与长双歧杆菌T(ATCC 15707)几乎相似的酶活性。特别地,长双歧杆菌CBT BG7显示出了在长双歧杆菌T(ATCC 15707)中未显示出的β-葡糖苷酶活性,该酶用于降解革兰氏阴性致病菌株细胞壁的肽聚糖中所含的葡萄糖,从而抑制致病菌株的生长。此外,长双歧杆菌CBT BG7没有显示出作为致癌酶的β-葡糖醛酸糖苷酶的活性。
表2
6)其他真菌学特征
根据本发明所述的长双歧杆菌CBT BG7的特征如下:
表3
基于上述结果,将分离的菌株命名为“长双歧杆菌CBT BG7”菌株,于2012年5月7日保藏于韩国典型培养物保藏中心(KCTC),该保藏中心是国际保藏机构,保藏号为KCTC12200BP。
1-3:功能性和稳定性
1)抗生素耐药性试验
为了验证分离的长双歧杆菌CBT BG7菌株(KCTC 12200BP)的安全性,分析了分离菌株的抗生素耐药性。抗生素耐药性测试使用由欧洲食品***(EFSA)推荐的微量稀释法进行,并且在测试中使用10种抗生素,包括氨苄青霉素(AMP)、万古霉素(VAN)、庆大霉素(GEN)、卡那霉素(KAN)、链霉素(STM)、红霉素(ERM)、奎奴普丁/达福普汀(Q/D)、克林霉素(CLM)、四环素(TET)和氯霉素(CP)。
对于不包括克林霉素的抗生素,将每种抗生素以256、128、64、32、16、8、4、2、1、0.5μg/ml的浓度加入到10%ISO-敏检肉汤和90%MRS肉汤的混合物中。克林霉素以16、8、4、2、1、0.5、0.25、0.125、0.0625和0.03125μg/ml的浓度添加,因为乳杆菌群的EFSA转效点值为0.25μg/ml或更少。此外,使用E测试条(BioMeriux)进行奎奴普丁/达福普汀(Q/D)的测试。
将微板在37℃下在厌氧条件下温育48小时,然后测量MIC作为没有观察到可见生长的最小抗生素浓度。
基于所述EFSA转效点,分析了长双歧杆菌CBT BG7是否对每种抗生素具有耐药性,并且分析的结果示于下表4中:
表4
显示出分离的长双歧杆菌CBT BG7菌株对所有在测试中使用的抗生素的耐药性均低于EFSA抗生素耐药性标准,表明分离的菌株满足EFSA抗生素的稳定性标准。由于据报道双歧杆菌因为不存在细胞色素介导的药物转运***而对氨基糖苷类如卡那霉素具有耐药性,所以EFSA不要求双歧杆菌的药物的MIC值。
2)肠道定殖测试
在来自人结肠上皮细胞的HT-29细胞系中进行了长双歧杆菌CBTBG7的肠道定殖的测量,同时将长双歧杆菌T(ATCC 15707)用作对照。将HT-29细胞系用每种菌株处理1小时,并进行革兰氏染色和活细胞计数以比较菌株之间的肠道定殖能力。测量结果示于下表5中。
表5
长双歧杆菌CBT BG7 | 长双歧杆菌T | |
肠道定殖率(%) | 92.15 | 83.40 |
肠道定殖的测量结果表明,长双歧杆菌CBT BG7菌株与长双歧杆菌T(ATCC 15707)菌株相比,显示出优异的肠道定殖能力。此种结果表明,本发明的菌株可以附着于肠上皮细胞以改善肠环境。
3)急性毒性测试
为了验证本发明的长双歧杆菌CBT BG7菌株的安全性,对试验动物进行急性毒性测试。以1.0×1011cfu/kg的量将本发明的冻干菌株口服施用于6周龄的雄性和雌性Sprague-Dawley(SD)大鼠。对于对照组,胃内施用0.85%盐水。每天观察一次所有试验动物中的临床症状,持续14天(从样品施用后1天到解剖日期的一段时间)。观察结果示于下表6中。
施用长双歧杆菌CBT BG7菌株后,在所有对照组和施用组中均未观察到死亡,并且没有发现显示特定临床症状的动物。另外,在施用后14天观察饲料和水的摄取和体温,结果未发现施用组和对照组之间统计学上的显著性差异。
表6
实施例2:长双歧杆菌CBT BG7菌株的基因分析
使用PacBio RS II***(DNA Link,Republic of Korea)进行长双歧杆菌CBT BG7菌株(KCTC 12200BP)的基因组测序。对于菌株的基因组,构建10-kb文库,并使用具有C2-P4化学的SMRT细胞之一进行基因组测序。通过基因组测序,获得长度为337,655,282bp的序列。使用SMRTpipe HGAP进行从头装配,并使用SMRTpipe AHA进行支架和间隙填充。使用Glimmer3进行结构基因的预测,并使用通过BLASTP获得的用于Pfam、Uniref100、KEGG、COG和GenBank NR数据库的结果,通过AutoFACT(Koski et al.2005)进行基因注释。分别使用tRNAscan-SE(Lowe和Eddy 1997)和RNAmmer(Lagesen et al.2007)进行转运RNA和核糖体RNA。使用RPS-BLAST在小于1e-2的e值截止值下进行直系同源群组(COG)类别的成簇对基因的功能分类(Mavromatis et al.2009).
对于收集的数据集,使用BLASTP以序列同源性≥50%的参数确定基因组上特定基因的存在。使用KEGG自动注释服务器进行基因组的代谢路径分析(Moriya et al.2007)。使用antiSMASH版本3.0.0进行次生代谢物生物合成基因的分析(Blin et al.2013;Blin etal.2014)(http://antismash.secondarymetabolites.org/)。
2-1:HMO(人乳寡糖)代谢相关基因
分析了根据本发明所述的长双歧杆菌CBT BG7菌株的基因组的基因内容。作为这种分析的结果,发现菌株的基因组含有人乳寡糖代谢相关基因中编码β-半乳糖苷酶、α-甘露糖苷酶和内桥-α-N-乙酰半乳糖胺酶的基因。这表明本发明的菌株可以消化和供应不被人酶消化的人乳寡糖(参见图5)。
表7
株菌 | 酶 | 登录号 |
长双歧杆菌CBT BG7 | β-半乳糖苷酶 | RY68_0416 |
长双歧杆菌CBT BG7 | β-半乳糖苷酶 | RY68_0534 |
长双歧杆菌CBT BG7 | β-半乳糖苷酶 | RY68_0735 |
长双歧杆菌CBT BG7 | α-甘露糖苷酶 | RY68_1335 |
长双歧杆菌CBT BG7 | α-甘露糖苷酶 | RY68_1336 |
长双歧杆菌CBT BG7 | 内桥-β-N-乙酰葡糖胺糖苷酶 | RY68_1329 |
长双歧杆菌CBT BG7 | 内桥-α-N-乙酰半乳糖胺酶 | RY68_0178 |
长双歧杆菌CBT BG7 | 内桥-α-N-乙酰半乳糖胺酶 | RY68_1842 |
2-2:维生素生物合成基因
基因分析结果表明,本发明的长双歧杆菌CBT BG7菌株具有从L-天冬氨酸合成B族维生素中的烟酸(B3)的基因。
表8
表9
2-3:抑制有害细菌的生长
为了检查本发明的菌株是否具有通过产生抗生素而抑制有害细菌生长的作用、分析了次级代谢产物生物合成基因和抗生素生产相关基因是否存在于长双歧杆菌CBT BG7菌株的基因组中。
检查了次级代谢物的生物合成。结果,如图6所示,发现本发明的长双歧杆菌CBTBG7菌株包括编码细菌素的基因。从这些结果可以看出,本发明的长双歧杆菌CBT BG7菌株可以通过产生抗生素化合物如细菌素来抑制致病菌的增殖。
2-4:缺乏致病基因
使用PAI数据库的PAI查找器进行PAI(致病性岛)和REI(抗菌性抗性岛)的分析(Yoon et al.2007;Yoon et al.2015)。分析结果表明,本发明的长双歧杆菌CBT BG7菌株的基因组中不存在PAI(致病性岛)和PAI样区域。
实施例3:长双歧杆菌CBT BG7菌株的生长促进效果
下面的实施例说明了本发明的菌株的特征和生长促进效果。在实施例中获得的所有实验结果均表示为平均值±SD,并使用GraphPad PrismTM 6.0进行实验结果的统计处理。此外,通过单因素ANOVA确定测试组之间平均值差异的显著性,然后使用Tukey的多范围测试进行Post Hoc测试。
3-1:本发明的菌株的培养物和包含其的组合物的制备
在37℃下将长双歧杆菌CBT BG7菌株(KCTC 12200BP)在BL肉汤(BD Diagnostics,Sparks,MD)中培养24小时,并且在磷酸盐缓冲盐水(PBS,10mM磷酸钠,130mM氯化钠,pH7.4)中稀释至1011CFU/ml。将稀释物超声处理并离心以分离上清液,随后通过孔径为0.45μm的过滤器过滤。将滤液冷冻干燥,然后储存在-20℃下直到用于体内实验。
3-2:肥胖动物模型和取样
根据机构动物护理和使用委员会(IACUC)的动物使用和护理方案进行动物试验。作为试验动物,使购自Saeron Bio Inc.(Uiwang,Korea)的6周龄SD大鼠(每组10只,由5只雄性大鼠和5只雌性大鼠组成)使用24小时。然后,在24±2℃的温度和55±15%的湿度下,以12小时光/12小时黑暗循环,将大鼠养育17天。对于基本饮食,允许大鼠服用大麦饲料(A04,UAR,Vilemoisson-sur-Orge,France)17天,并还允许自由地饮用单独的饮用水或饮用含有长双歧杆菌CBT BG7(107CFU/头/天)的饮用水。
3-3:本发明菌株的生长促进效果
为了观察本发明的长双歧杆菌CBT BG7菌株的生长促进效果,用大麦饲料喂养大鼠17天以诱导基本饮食,并且每天测量体重以及饮用水和饲料的摄入量直到实验开始后的第17天。通过从测量当天的体重减去实验开始日的体重来计算体重的增加。通过测量每笼的摄入量,然后计算每只大鼠的摄入量,计算饮用水和饲料中每一种的摄入量,作为直到第17天的总摄入量。通过将体重的增加除以饲料的总摄入量来计算体重增加的效率。
参见图7,观察到,在喂养含有长双歧杆菌CBT BG7的饮用水的组(CBT BG7)的情况下,与正常喂养普通食用水的组(NC)相比,体重自第9天显著增加(12天;p<0.05,13至17天;p<0.01)(图7(A))。然而,17天的饲料总摄入量(FI)和17天的饮用水的总摄入量(WI)在两组之间没有显着差异(图7(B))。可以看出,施用本发明的菌株不影响采食量,并且体重增加(WG)不能归因于采食量(FI)的差异。与正常组相比,长双歧杆菌CBT BG7喂养组中的体重增加与体重增加的比值(WG/FI)更显著,表明通过施用本发明的长双歧杆菌CBT BG7菌株促进了大鼠的生长。
已经以本发明的优选实施方式为重点描述了本发明。具有本发明所属领域普通知识的人员能够理解,在不脱离本发明的本质特征的情况下,本发明可以以各种修改或改变的形式实施。因此,本发明的真正保护范围应当由所附权利要求及其等同范围来限定,而不是由上述实施方式限定。
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
国际保藏机构根据细则第7.1条出具的原始保藏的收据
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si
Gyeonggi-do 415-872,Republic of Korea
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
根据细则第8.2条关于科学说明和/或建议的分类名称的后来载明或修正的证明
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si
Gyeonggi-do 415-872,Republic of Korea
附件:根据细则第8.1条的关于科学说明和/或分类名称的后来载明或修正的通信。
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
国际保藏机构根据细则第7.1条出具的原始保藏的收据
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si,
Gyeonggi-do 415-872,Republic of Korea
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
根据细则第8.2条关于科学说明和/或建议的分类名称的后来载明或修正的证明
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si
Gyeonggi-do 415-872,Republic of Korea
附件:根据细则第8.1条的关于科学说明和/或分类名称的后来载明或修正的通信。
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
国际保藏机构根据细则第7.1条出具的原始保藏的收据
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si
Gyeonggi-do 415-872,Republic of Korea
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
根据细则第8.2条关于科学说明和/或建议的分类名称的后来载明或修正的证明
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si
Gyeonggi-do 415-872,Republic of Korea
附件:根据细则第8.1条的关于科学说明和/或分类名称的后来载明或修正的通信。
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
国际保藏机构根据细则第7.1条出具的原始保藏的收据
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si
Gyeonggi-do 415-872,Republic of Korea
关于国际承认用于专利程序的微生物保藏的布达佩斯条约
根据细则第8.2条关于科学说明和/或建议的分类名称的后来载明或修正的证明
致:Myung-Jun,Jung
134,Gaegok-ri,Wolgot-myeon,Gimpo-si
Gyeonggi-do 415-872,Republic of Korea
附件:根据细则第8.1条的关于科学说明和/或分类名称的后来载明或修正的通信。
Claims (6)
1.一种用于促进生长的长双歧杆菌CBT BG7双歧杆菌,其国际保藏于韩国生物科学和生物技术研究所的韩国典型培养物保藏中心(KCTC),保藏号为KCTC 12200BP。
2.如权利要求1所述的双歧杆菌,其具有降解人乳寡糖的基因,其中所述基因包括编码β-半乳糖苷酶、α-甘露糖苷酶和内桥-α-N-乙酰半乳糖胺酶的基因。
3.如权利要求1所述的双歧杆菌,其包含从L-天冬氨酸合成烟酸(B3)的基因。
4.一种营养组合物,其包含根据权利要求1所述的长双歧杆菌CBT BG7菌株(KCTC12200BP)。
5.如权利要求4所述的营养组合物,其以108~1012cfu/ml的量包含长双歧杆菌CBT BG7菌株(登录号:KCTC 12200BP)的活细菌或干细菌。
6.如权利要求4所述的营养组合物,其进一步包含从由长双歧杆菌亚种婴儿BT1(KCTC11859BP)、短双歧杆菌CBT BR3(KCTC 12201BP)和两歧双歧杆菌CBT BF3(KCTC 12199BP)组成的组中选择的一种或多种其它益生元。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110820791.2A CN113367346A (zh) | 2015-05-21 | 2015-07-13 | 用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150071124A KR101589466B1 (ko) | 2015-05-21 | 2015-05-21 | 성장 촉진을 위한 비피도박테리움 롱굼 cbt bg7 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 |
KR10-2015-0071124 | 2015-05-21 | ||
PCT/KR2015/007227 WO2016186245A1 (ko) | 2015-05-21 | 2015-07-13 | 성장 촉진을 위한 비피도박테리움 롱굼 cbt bg7 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110820791.2A Division CN113367346A (zh) | 2015-05-21 | 2015-07-13 | 用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106715680A true CN106715680A (zh) | 2017-05-24 |
Family
ID=55354117
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580035822.6A Pending CN106715680A (zh) | 2015-05-21 | 2015-07-13 | 用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 |
CN202110820791.2A Pending CN113367346A (zh) | 2015-05-21 | 2015-07-13 | 用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110820791.2A Pending CN113367346A (zh) | 2015-05-21 | 2015-07-13 | 用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20180179603A1 (zh) |
EP (1) | EP3135754B1 (zh) |
JP (1) | JP6499212B2 (zh) |
KR (1) | KR101589466B1 (zh) |
CN (2) | CN106715680A (zh) |
SG (1) | SG11201608731XA (zh) |
WO (1) | WO2016186245A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111935995A (zh) * | 2018-03-29 | 2020-11-13 | 森永乳业株式会社 | 营养组合物以及使用了该营养组合物的饮食品组合物和配方奶粉 |
CN115354009A (zh) * | 2022-10-20 | 2022-11-18 | 东北农业大学 | 一种具有菌毛的长双歧杆菌婴儿亚种及其应用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113730442A (zh) | 2014-10-31 | 2021-12-03 | 潘德勒姆治疗公司 | 与病症的微生物治疗和诊断有关的方法和组合物 |
KR101589465B1 (ko) * | 2015-05-21 | 2016-02-01 | 주식회사 쎌바이오텍 | 성장 촉진을 위한 비피도박테리움 브레베 cbt br3 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 |
JP6766253B2 (ja) | 2017-03-28 | 2020-10-07 | 森永乳業株式会社 | 新規ビフィドバクテリウム属細菌 |
CA3073838A1 (en) | 2017-08-30 | 2019-03-07 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
CN112501049B (zh) * | 2020-10-28 | 2022-04-19 | 石河子大学 | 产转糖基活性β-半乳糖苷酶的开菲尔乳杆菌及制备的β-半乳糖苷酶生产低聚半乳糖的方法 |
CN112813134B (zh) * | 2021-04-07 | 2022-04-26 | 河北一然生物科技股份有限公司 | 显色培养基、制备方法及菌株检测方法 |
CN114525218B (zh) * | 2021-12-30 | 2024-05-07 | 美益添生物医药(武汉)有限公司 | 一种长双歧杆菌及其培养方法和其在高产γ-氨基丁酸和5-羟色胺中的应用 |
CN115011518A (zh) * | 2022-06-13 | 2022-09-06 | 东北农业大学 | 一种具有缓解结肠炎相关结直肠癌作用的乳酸菌混合物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007046697A1 (en) * | 2005-10-21 | 2007-04-26 | N.V. Nutricia | Method for treating and/or preventing infections in infants delivered via caesarean section |
EP2240186A1 (en) * | 2008-02-12 | 2010-10-20 | N.V. Nutricia | A composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100472865B1 (ko) * | 2002-08-28 | 2005-03-10 | (주) 피엘바이오 | 생리활성이 뛰어난 한국형 비피도박테리움 인판티스 pl9506 |
KR100865363B1 (ko) * | 2002-09-16 | 2008-10-24 | 매일유업주식회사 | 비피도박테리움 인팬티스 maeil-k9 비피더스유산균 및 그를 함유하는 건강기능성 식품 |
KR100492455B1 (ko) * | 2003-09-26 | 2005-05-30 | 주식회사 비피도 | 로바타바이러스 억제활성을 갖는 신균주 비피도 박테리움 롱검 에이알81 및 이로부터 분리된 활성단백질 |
KR100530211B1 (ko) | 2003-12-29 | 2005-11-22 | 양순길 | 학습능력을 향상시키는 건강기능식품 조성물 및 그 제조방법 |
US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
KR100561286B1 (ko) | 2004-05-19 | 2006-03-15 | 일양약품주식회사 | 건조효모, 천연물 추출분말 및 영양성분 혼합분말을함유하여 성장발육에 도움을 주는 건강기능성 조성물 |
KR100887377B1 (ko) | 2007-03-09 | 2009-03-05 | 김재현 | 유아 및 청소년을 위한 건강보조식품 |
CN101560523B (zh) * | 2008-04-17 | 2011-08-17 | 吴炳新 | 基于五株益生菌混合发酵培养物的营养组合物 |
EP2609813A1 (en) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system |
CN104472695B (zh) * | 2013-12-27 | 2017-10-24 | 光明乳业股份有限公司 | 一种儿童型酸奶粉及其制备方法 |
KR101453984B1 (ko) * | 2014-02-24 | 2014-10-28 | 주식회사 쎌바이오텍 | 과민성 대장 증후군 예방 또는 치료용 조성물 |
KR101589465B1 (ko) * | 2015-05-21 | 2016-02-01 | 주식회사 쎌바이오텍 | 성장 촉진을 위한 비피도박테리움 브레베 cbt br3 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 |
-
2015
- 2015-05-21 KR KR1020150071124A patent/KR101589466B1/ko active IP Right Grant
- 2015-07-13 CN CN201580035822.6A patent/CN106715680A/zh active Pending
- 2015-07-13 JP JP2016576074A patent/JP6499212B2/ja active Active
- 2015-07-13 EP EP15890172.8A patent/EP3135754B1/en active Active
- 2015-07-13 CN CN202110820791.2A patent/CN113367346A/zh active Pending
- 2015-07-13 US US15/310,299 patent/US20180179603A1/en not_active Abandoned
- 2015-07-13 WO PCT/KR2015/007227 patent/WO2016186245A1/ko active Application Filing
- 2015-07-13 SG SG11201608731XA patent/SG11201608731XA/en unknown
-
2019
- 2019-04-04 US US16/374,885 patent/US10597740B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007046697A1 (en) * | 2005-10-21 | 2007-04-26 | N.V. Nutricia | Method for treating and/or preventing infections in infants delivered via caesarean section |
EP2240186A1 (en) * | 2008-02-12 | 2010-10-20 | N.V. Nutricia | A composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants |
Non-Patent Citations (3)
Title |
---|
강주연等: "Dual Coating Improves the Survival of Probiotic Bifidobacterium Strains during Exposure to Simulated Gastro-Intestinal Conditions", 《KOREAN JOURNAL OF MICROBIOLOGY》 * |
吴炳新等: "双歧杆菌复合制剂(三株口服液)对儿童生长和智力发育的促进作用", 《中国微生态学杂志》 * |
齐景伟: "《反刍动物生物饲料开发与应用》", 30 April 2014 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111935995A (zh) * | 2018-03-29 | 2020-11-13 | 森永乳业株式会社 | 营养组合物以及使用了该营养组合物的饮食品组合物和配方奶粉 |
CN115354009A (zh) * | 2022-10-20 | 2022-11-18 | 东北农业大学 | 一种具有菌毛的长双歧杆菌婴儿亚种及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3135754B1 (en) | 2021-06-23 |
JP6499212B2 (ja) | 2019-04-10 |
CN113367346A (zh) | 2021-09-10 |
US20180179603A1 (en) | 2018-06-28 |
SG11201608731XA (en) | 2016-12-29 |
EP3135754A1 (en) | 2017-03-01 |
US10597740B2 (en) | 2020-03-24 |
US20190256934A1 (en) | 2019-08-22 |
JP2017521071A (ja) | 2017-08-03 |
EP3135754A4 (en) | 2017-12-27 |
WO2016186245A1 (ko) | 2016-11-24 |
KR101589466B1 (ko) | 2016-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018229410B2 (en) | Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity | |
CN106715680A (zh) | 用于促进生长的长双歧杆菌cbt bg7菌株和用于促进生长的含有该菌株的营养组合物 | |
Leahy et al. | Getting better with bifidobacteria | |
Mahious et al. | Effect of dietary inulin and oligosaccharides as prebiotics for weaning turbot, Psetta maxima (Linnaeus, C. 1758) | |
CN104080903B (zh) | 从猪分离的菌株 | |
US11026983B2 (en) | Bifidobacterium breve CBT BR3 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same | |
CN109475169A (zh) | 促进哺乳动物免疫***成熟的方法 | |
CN109310715A (zh) | 用于促进运动表现的益生菌制剂 | |
CN109415683A (zh) | 新细菌物种 | |
KR101589464B1 (ko) | 신규한 비피더스 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 | |
US8728461B2 (en) | Lactic acid bacterium having high immunoglobulin-A-inducing ability | |
Geigerová et al. | Selection of prebiotic oligosaccharides suitable for synbiotic use in calves | |
JP7261867B2 (ja) | 骨格筋遅筋化用組成物 | |
KR100868777B1 (ko) | Rs3 유형의 저항 전분에 대해 분해능이 있는비피도박테리움 아도레스센티스를 유효성분으로 함유하는것을 특징으로 하는 식품 조성물 | |
O'Sullivan | Primary sources of probiotic cultures | |
KR101589467B1 (ko) | 성장 촉진을 위한 비피도박테리움 비피둠 cbt bf3 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물 | |
Kumari et al. | Probiotics: from Science to Technology | |
US20120177607A1 (en) | Oxidative stress resistant bifidobacteria | |
Sajnani et al. | Whole-Genome Shotgun Sequencing of | |
GUIDESI | INTEGRATED APPROACH TO THE SELECTION OF NEW PROBIOTICS FOR HUMAN APPLICATION | |
Baffoni | Use of probiotics and prebiotics: a strategy to modulate the intestinal microbiota of poultry and control C. jejuni colonization | |
Van der Westhuizen | The potential of neokestose as a prebiotic for broiler chickens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |
|
RJ01 | Rejection of invention patent application after publication |